Caution using hypomethylating agents in myelodysplasia or myeloid leukemia with complex cytogenetics

Journal of Clinical Oncology

Volumn 28, Issue 22, 2010, Pages

  Turturro, Francesco ^a   Leary, Cheri ^a   Stephens, Johnny ^a   Veillon, Diana ^a   Lowery Nordberg, Mary ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AZACITIDINE; HYPOMETHYLATING AGENT; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; BONE MARROW BIOPSY; CASE REPORT; CHROMOSOME 11; CHROMOSOME 12; CHROMOSOME 16; CHROMOSOME 17; CHROMOSOME 20; CHROMOSOME 5Q; CHROMOSOME 7Q; CHROMOSOME DELETION; CHROMOSOME GAIN; CHROMOSOME LOSS; CYTOGENETICS; DRUG SAFETY; FEMALE; HUMAN; HUMAN TISSUE; LETTER; MALIGNANT TRANSFORMATION; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NUMERICAL CHROMOSOME ABERRATION; PRIORITY JOURNAL; BLAST CELL CRISIS; GENETICS; MIDDLE AGED; MYELOID LEUKEMIA; NOTE;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BLAST CRISIS; CHROMOSOME DELETION; FEMALE; HUMANS; LEUKEMIA, MYELOID; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES;

EID: 77955893574     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.28.5775     Document Type: Letter

References (11)

1. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al: Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 28:562-569, 2010
2. Fenaux P, Mufti HJ, Hellstrom-Lindberg E, et al: Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomized, open-label, phase II study. Lancet Oncol 10:223-232, 2009
3. Kantarjian H, Issa JP, Rosenfeld CS, et al: Decitabine improves patient outcomes in myelodysplastic syndromes. Cancer 106:1794-1803, 2006
4. Lubbert M, Wijermans P, Kunzmann R, et al: Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with DNA methylation inhibitor 5-aza-2′-deoxycytidine. Br J Haematol 114:349-357, 2001 (Pubitemid 32762234)
5. Gatenby RA, Silva AS, Gillies RJ, et al: Adaptive therapy. Cancer Res 69:4894-4903, 2009
6. Vardiman JW, Harris NL, Brunning RD: The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100:2292-2302, 2002
7. Ades L, Boehre S, Prebet T, et al: Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: Results of a phase 2 study. Blood 113:3947-3952, 2009
8. Jadersten M, Saft L, Pellagatti A, et al: Clonal heterogeneity in the 5q-syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression. Haematologica 94:1762-1766, 2009
9. Lyons RM, Cosgriff TM, Modi SS, et al: Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol 27:1850-1856, 2009
10. Chandler JC, Klisovic RB, Phelps MA, et al: Phase I study of lenalidomide in acute leukemia: Remissons in post-allogeneic relapse of acute myeloid leukemia. Blood 114:346, 2009 (abstr 841)
11. Vij R, Nelson A, Uy GL, et al: A phase II study of high dose lenalidomide as initial therapy for acute myeloid leukemia in patients > 60 years old. Blood 114:347, 2009 (abstr 842)